Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aurinia rises as regulators clarify path for voclosporin

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) said it believes results from a planned Phase III study and a completed

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE